201,966 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Acquired by Wellington Management Group LLP

Wellington Management Group LLP bought a new stake in Applied Therapeutics, Inc. (NASDAQ:APLT) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 201,966 shares of the company’s stock, valued at approximately $1,717,000.

Other large investors have also recently bought and sold shares of the company. Victory Capital Management Inc. purchased a new stake in shares of Applied Therapeutics in the second quarter valued at $54,000. Principal Financial Group Inc. acquired a new position in Applied Therapeutics in the 2nd quarter valued at about $54,000. SG Americas Securities LLC purchased a new position in Applied Therapeutics in the 2nd quarter valued at about $87,000. Intech Investment Management LLC acquired a new stake in shares of Applied Therapeutics during the 3rd quarter worth about $162,000. Finally, Algert Global LLC purchased a new stake in shares of Applied Therapeutics during the second quarter worth about $110,000. Institutional investors and hedge funds own 98.31% of the company’s stock.

Applied Therapeutics Trading Down 1.8 %

Shares of Applied Therapeutics stock opened at $1.08 on Thursday. The stock has a market capitalization of $125.66 million, a P/E ratio of -0.67 and a beta of 1.76. The business’s fifty day moving average price is $6.93 and its 200 day moving average price is $6.18. Applied Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $10.62.

Wall Street Analyst Weigh In

APLT has been the topic of several recent analyst reports. Robert W. Baird reduced their price objective on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, November 29th. Citigroup reduced their price target on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. UBS Group reaffirmed a “neutral” rating and issued a $2.00 price objective (down previously from $13.00) on shares of Applied Therapeutics in a research report on Monday, December 2nd. Leerink Partners raised their price target on Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Finally, Royal Bank of Canada cut Applied Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $12.00 to $4.00 in a report on Friday, November 29th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.60.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.